在TDP-43A315T小鼠模型中,白色脂肪组织经历了病理功能障碍,即肌缩侧面硬化症 (ALS)
Cristina Benito-Casado1, Esther Durán-Mateos2, Águeda Ferrer-Donato1
1Department of Health and Pharmaceutical Sciences, School of Pharmacy, Universidad CEU-San Pablo, Urbanización Monteprincipe, Boadilla del Monte, 28660, Madrid, Spain.
Acta neuropathologica communications
|October 10, 2025
概括
白色脂肪组织 (WAT) 在ALS小鼠中显示早期组织学变化. 患有ALS的男性中较低的瘦素水平与快速进展相关,突出了性别特定的代谢作用.
科学领域:
- 代谢研究的研究.
- 神经退行性疾病机制的神经退行性疾病机制
- 脂肪组织生物学 脂肪组织生物学
背景情况:
- 白色脂肪组织 (WAT) 对于能量平衡至关重要,并且与肌缩侧面硬化症 (ALS) 的代谢功能障碍有关.
- 精确的分子机制和WAT在ALS相关代谢异常中的直接作用尚未完全理解.
- 阿迪波金和叶丁一样,在新陈代谢调节中起着关键作用,但它们在ALS病变发生中的具体参与需要进一步调查.
研究的目的:
- 在TDP-43A315T小鼠的ALS临床过程中调查WAT的变化.
- 为了在ALS的小鼠模型中识别症状发作之前的WAT早期病理变化.
- 在人类ALS病例中检查循环勒丁水平,疾病进展和患者特征之间的关系.
主要方法:
- 组织学,蛋白质学和分子生物学技术用于分析TDP-43A315T小鼠中的WAT.
- 对WAT样本进行了评估,以确定不同疾病阶段的病理变化.
- 在人类ALS患者的诊断时,测量了循环勒丁水平,考虑了性别,BMI和疾病进展率等因素.
主要成果:
- 该研究发现TDP-43A315T小鼠在疾病症状出现之前的WAT具有显著的组织学变化.
- 这些发现表明,在这种ALS模型中,WAT是早期受影响的器官.
- 在男性ALS患者中观察到较低的血瘦素水平,这些患者超重/肥胖且疾病进展迅速.
结论:
- 在ALS小鼠模型中,WAT表现出早期的病理变化,这表明它是一个潜在的目标器官.
- 亚迪波金水平的性别特异性差异,如瘦素,在ALS中是相关的,可能会影响疾病的进展.
- 对WAT和阿迪波金功能的进一步研究对于理解和潜在的治疗ALS至关重要,考虑到性别特异性因素.
相关概念视频
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...


